IL6 and graft versus host disease: Blockade of the pro-inflammatory effects of IL-6 seems to be a possible therapeutic strategy since IL-6 and STAT3 activation are closely linked to the development of both Th17 and Treg cells, and since early STAT3 phosphorylation posttransplant seems to precede development of GVHD (118).